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Summary The mechanism of action of the novel heterocycle 3,5-dimethyl-pyrido-1,2,3,5-tetrazepin-4-one (PYRZ), structurally related to
temozolomide, was studied in the human ovarian tumourcell line OVCAR-3. Our results showed that, despite its marked structural similarities
to temozolomide, PYRZ presents properties that are atypical of 1,2,3-triazene-containing alkylating agents. In a Maxam-Gilbert DNA
sequencing assay, PYRZ showed background levels of DNA alkylation, in contrast to temozolomide which strongly alkylated DNA
preferentially at guanine residues. At high concentrations, PYRZ inhibited the synthesis of DNA, RNA and protein 3 h after treatment, in
contrast to temozolomide which, in previous work, was found to preferentially inhibit DNA synthesis in OVCAR-3 cells. In cells exposed to
PYRZ, alkaline sucrose density-gradient centrifugation showed a dose-dependent increase in DNA fragmentation only 12 and 24 h after
treatment. PYRZ induced increasing accumulation of cells in late S and G2+M 6-24 h after treatment. This also contrasts with previous work
that showed delayed cell cycle arrest induced by temozolomide in OVCAR-3 cells and in the murine leukaemia Li 210 cells. Cell-killing
kinetics by PYRZ showed a series of sigmoidal dose-response curves with 50-90% cell killing attained as early as 24 h after treatment in the
25-100 gM dose range. (IC50 clonogenic assay 18 FM). The results suggest that the mechanism of cell killing by PYRZ may be different from
that of its parent drug temozolomide, and other alkyl-triazene-containing molecules of the same class.
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Temozolomide (1) is a tetranitrogen heterocycle with significant
clinical activity against malignant melanoma, high-grade glioma
and mycosis fungoides (Foedstad etal, 1985; O'Reilly etal, 1993).
Recently, it has been shown in a pilot study to be extremely active
in patients with primary brain tumours who relapsed following
radiotherapy. Under physiological conditions, temozolomide
generates a monomethyltriazene species that alkylates DNA (Baig
et al, 1987). There is accumulating evidence to show that only the
alkylation of guanine at the 06 position is the critical event
leading to cell death. Cells containing 06-alkylguanine transferase
(AGT), an enzyme capable ofrepairing this lesion, are resistant to
temozolomide (Catapano et al, 1987; Deans et al, 1992; Baer et al,
1993). This limit is also known for other alkylating agents such as
alkylnitrosoureas and alkyltriazenes (Gibson et al, 1986; Hartley
et al, 1986; Chen et al, 1993).
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Recently, we have designed a novel class of heterocycles based
on the structural modification of the 1,2,3,5-tetrazin-4-one back-
bone of temozolomide: the 1,2,3,5-tetrazepin-4-ones (Jean-Claude
and Just, 1991; Jean-Claude, 1992; Jean-Claude et al, 1994, 1996,
1997). Taking the bridge nitrogen out of the aromatic system and
keeping it electron poorby placing it in the 2-position ofa pyridine
ring gave the 6-7 fused heterocycle (2; PYRZ). The latter
compound andother 1,2,3,5-tetrazepin-4-one ring-containing deriv-
atives were found to show significant cytotoxicity in a panel of
human tumour cell lines, including high AGT-expressing brain,
breast and colon tumour cells (Jean-Claude et al, 1995). Although
the new compounds share structural similarities witti temozolo-
mide, they exhibit markedly different chemical properties. As an
example, X-ray crystallography shows that PYRZ adopts a non-
planar seven-membered ring boat shape (Figure 1), whereas temo-
zolomide is almost perfectly planar (Clark et al, 1990; Lowe et al,
1992). (The X-ray data supporting this conformation have been
submitted to the journal as supplementary materials). Chemical
differences between temozolomide andthetetrazepinonesprompted
us to investigate the mechanism ofthe in vitro action ofthe latter.
This study describes the effects of tetrazepinone (2; PYRZ) on
the human ovarian tumour cell line OVCAR-3. The effects are
occasionally compared with that of temozolomide. PYRZ showed
rapid cell-killing kinetics and an ability to induce detectable single-
strand breaks in OVCAR-3 cells only 12 and 24 h after treatment.
PYRZ was capable ofinducing significant cell cycle arrest in late S
and G2+M as early as 6 h after treatment. This drug did not appear
to be an inhibitor ofDNA synthesis.
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Figure 1 6-3-11G* (Krishnan et al) geometry optimization from X-ray
crystallographic data obtained for PYRZ
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Figure 3 Effects of PYRZ on DNA, RNA and protein syntheses in OVCAR-3
cells. (A) 3 h after treatment (B) 24 h after treatment. Data are means and
s.d. of at least two independent experiments run in triplicate
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Figure 2 (A) Survival of clonogenic cells from the OVCAR-3 cell line after in
vitro exposure for 2 h at 370C to increasing concentrations of PYRZ.
Colonies were counted 11 days after treatment. (B) Cell-killing kinetics
by PYRZ as determined by the sulphorhodamine B assay. Points in A
and B represent means and s.e. obtained from two separate experiments
and IC50 values were determined by a sigmoidal dose-response curve fit
(variable slope)
MATERIALS AND METHODS
Drug treatment
PYRZ was synthesized at the Department of Chemistry, McGill
University (Jean-Claude et al, 1991; Jean-Claude and Just, 1997).
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Figure 4 Kinetics of thymidine transport in OVCAR-3 cells exposed to PYRZ
at 3 h after treatment (one experiment in duplicate)
In all assays, the drug was dissolved in dimethyl sulphoxide
(DMSO) and diluted in sterile RPMI medium immediately before
treatment of cell cultures. The concentration of DMSO never
exceeded 2% (v/v). The cells were treated with PYRZ for 2 h and
treatments were terminated by aspiration of the drug-containing
medium and replacement with fresh RPMI-1640 medium. Under
continuous exposure, the cells were kept in drug-containing
medium for the specified time periods.
British Journal ofCancer (1997) 76(4), 467-473
-0- DNA
A RNA
V Protein
Concentration (gM)
n U
0CancerResearch Campaign 1997
k
.16
AE as6 h 12 h 24 h
A
B
D L~~~~~ L
E
F
DNA content
(relative fluorescence)
Figure 5 DNA histograms of exponentially growing OVCAR-3 cells at various time periods after a 2 h exposure to PYRZ. (A) 0 gm; (B) 12.5 rM; (C) 25 gm; (D) 50 mr; (E) 100 gm; (F) 200 FM. Cells taken at different times during drug exposure were analysed by flow cytometry. Left peak, G, cells; right peak,
G2M cells. S-phase cells occupy the area between the two peaks
Cell culture
The OVCAR-3 cells (Hamilton et al, 1983) obtained from the
National Cancer Institute (NCI) were maintained as a monolayer
culture at 37°C in a humidified atmosphere of 5% carbon
dioxide/95% air in RPMI-1640 medium supplemented with fetal
bovine serum (10%), L-glutamine (2 mM), penicillin (50 U ml-1)
and streptomycin (50 mg ml-'). Cells were maintained in loga-
rithmic growth by harvesting with a trypsin/EDTA solution
containing 0.5 mg ml of trypsin and 0.2 mg ml-' of EDTA, and
replating before cells reached confluency. Growth studies showed
a doubling time ofapproximately 30 h. In all assays, the cells were
plated for 24 h before drug administration.
Cytotoxicity and cell-killing kinetics
Cell monolayers were incubated with varying amounts of PYRZ
for different time periods (continuous exposure) and cytotoxicity
evaluated by the sulphorhodamine B assay (Skehan et al, 1991).
Briefly, at each appropriate time, the cells were fixed by the addi-
tion of 50 ,l of cold trichloroacetic acid (TCA) (50%) at 40C for
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Figure 6 DNA alkylation produced by temozolomide and PYRZ at an
equimolar concentration (1 mm) in the HinidlI/Sphl sequence of SV40 DNA.
Lane A, control piperidine treated DNA; lane B, purine-specific cleavage;
lane C, guanine-specific cleavage; lane D, temozolomide (1 mm)-treated
DNA; lane E, PYRZ (1 mm) treated DNA. A typical guanine-rich region is
indicated
60 min. The wells were washed four times with water and stained
with sulphorhodamine B (0.4%) dissolved in 1% acetic acid. The
plates were air dried and the resulting coloured residue dissolved
in 200 ,ul of Tris base (10 mM). The optical density (OD) of each
well was measured at 540 nm with a BioRad microplate reader
(model 3550). Points represent the average of two independent
experiments run in triplicate.
Clonogenic assay
Colony formation was assayed by exposure of OVCAR-3 cells to
PYRZ in 25-cm2 flasks. Cells were plated at a density of 50 000
cells in RPMI medium supplemented with 10% fetal bovine
serum, which yielded approximately 1500 colonies per flask in
untreated controls. After 24 h, cells were treated with a dose range
of PYRZ for 2 h and then allowed to recover in drug-free media.
Colonies were counted with an Artek Omnicon 880 counter,
following incubation of the plated cells under routine conditions
for 7 days, by which time colonies greater than 60 m were
enumerated. Within experiments, percentage clonogenic survival
was determined as the mean number of colonies from duplicate
platings at each drug concentration relative to untreated controls.
Macromolecule synthesis
DNA, RNA and protein synthesis were determined by adding
radioactive precursors [methyl-3H]thymidine (sp. act., 20 mCi
mmol-1), [5-3H]uridine (sp. act., 20 mCi mmol-1) or L-[4,5,3H]-
leucine (sp. act., 120-190 Ci mmol-') to the cell culture medium for
3 h. [Methyl-3H]thymidine, [5-3H]uridine (obtained from New
England Nuclear) were added at 0.5 ,uCi mll andL-[4,5-3H]leucine
at 1 ,uCi ml-'. At the end of radioisotope incubation, cells were
trypsinized and an aliquot (0.1 ml) was collected forcell counts in a
ZM Coulter counter before centrifugation. The supematant was
removed and replaced with cold 10% TCA (1 ml). The resulting
precipitate was collected by centrifugation and digested in sodium
hydroxide (0.1 N). The mixture was neutralized, transferred to a
scintillation vial and dissolved in 3 ml of liquid scintillation fluid
(Universol). The associated radioactivity was counted in a beta-
scintillation spectrometer. The level ofincorporation was expressed
as c.p.m. per cell and the percent control calculated as:
c.p.m. 10-5 cells treated
c.p.m. 10-5 control cells
Each point represents the average and standard error resulting
from at least two independent experiments run in duplicate.
Flow cytometry
The effect of a 2-h exposure to PYRZ on the cycle of OVCAR-3
cells was evaluated after recovery times of 6, 12 and 24 h. The
cells were harvested by trypsinization at the appropriate times.
After fixation in ethanol (70%, v/v), the cells were stained with an
aqueous propidium iodide (PI) solution (100 pl, 100 gg ml-')
containing RNAase (100 gl, 50 gg ml-') for 30 min at room
temperature in the dark. The fluorescence was detected in a spec-
tral range between 580 and 750 nm. Each cytometric analysis
was performed on a Becton Dickinson FACScan instrument on
1-3 x 105 cells. The percentage of cells in each cell cycle phase
was estimated using LYSYS II software (Becton Dickinson).
Transport study
Studies on kinetics of precursor transport were performed as
described previously (Hayward et al, 1984). The OVCAR-3 cells
were seededfor24hin 24-well plates atadensity of6x 105cellsper
well. PYRZ was added to the medium at various concentrations.
After a 2-h treatment the drug was removed by washing with phos-
phate-buffered saline (PBS) (2 x 2 ml) andfresh medium was added.
The cells were allowed to recover for 3 h, after which fresh medium
containing 0.3 ,uCi ml-' [14C]thymidine was added. Label uptake was
allowed to proceed for various intervals at 0°C (2, 5, 10, 20 or
35 min). The medium was removed and the wells rapidly washed
with cold PBS (2 x 2 ml). The cells were detached with 100 ,l of
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Figure 7 DNA damage induced by PYRZ in OVCAR-3 cells. (-+-) Internal control 140-labelled DNA from untreated cells; (-z) [3H]thymidine DNA from treated
cells. (A) 0 gM; (B) 50 gM; (C) 100 gM; (D) 200 gM
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trypsin and dissolved in 3 ml ofliquid scintillation fluid (Universol).
The radioactivity was counted in a beta-scintillation counter.
Sequence specificity of guanine-N-7 alkylation
Plasmid pRGM21, which was used to determine guanine specific
N-7 alkylation, has been described in detail (Nobile et al, 1986).
Briefly, the wild-type SV40 origin ofreplication from the HindIll
to SphI site (200 bp) was inserted between the HindlIl and SphI
sites of pBR322. Using PCR, the SV40 region of the plasmid was
amplified with the following primers: 5'-GGCCATCCAGCCTCG-
3 and 5'-GTATCACGAGGCCCT-3'. The latter primer was end
labelled (T4 polynucleotide kinase, Gibco BRL) with [y-32P]ATP
(ICN Biomedical). The amplified labelled DNA (700 bp) was
reacted with 1 mm PYRZ or temozolomide in 25 mm tri-
ethanolamine-I mm EDTA, pH 7.2, at 37°C for 2 h. After precipi-
tation and washing the DNA was treated with 1 M piperidine for
15 min at 90°C to produce breaks specifically at the sites of N-7
guanine alkylation. DNA fragments were separated on a 0.4-mm,
6% polyacrylamide gel in a solution containing 7 M urea and a
Tris-boric acid-EDTA buffer system.
Alkaline sucrose gradient
Cells were labelled for 24 h using a medium supplemented with
0.1 jCi ml' [3H]- or ['4C]thymidine for internal control cells
(Zsido et al, 1991). Post-labelling (18-24 h) was performed before
drug treatment. The drug was added for 2 h and the cells were
allowed to grow in fresh medium for 24 h. They were then washed
twice with PBS and dislodged by gentle scraping. To the 3H-
labelled cells was added an aliquot of untreated 14C-labelled cells
to serve as internal control during sedimentation analysis. The
cells were then lysed in the dark at 0°C (lysis buffer: 0.55 N
sodium hydroxide, 0.45 M sodium chloride, 10 mM Na2 EDTA,
0.015% sarcosyl) and layered on the top of 5-30% sucrose gradi-
ents containing 0.3 N sodium hydroxide, 0.7 M sodium chloride,
and 10 mM Na2EDTA. Sedimentation was carried out at 4°C in a
SW41 rotor of a centrifuge usually at 16 000 r.p.m. overnight.
Gradients were fractioned by upward displacement with 1 ml of a
dye dissolved in 40% sucrose and the samples collected with a
BioRad fraction collector. The 0.3-ml fractions were analysed by
single-phase liquid scintillation counting (dual-label settings).
RESULTS
Cytotoxicity
Survival curves for OVCAR-3 cells treated with PYRZ are shown
in figure 2A and B. A clonogenic assay gave anIC50 of 18gM. The
cell-killing kinetics, as determined by the sulphorhodamine B
assay, showed that the rate of cell kill was rapid and time depen-
dent only beyond a critical dose (around 20 JUM). At high concen-
trations (50-100gM), 90% kill was achieved within 24 h.
Macromolecule synthesis
The effect of PYRZ on precursor incorporation was evaluated and
the results are shown in Figure 3. Following a 2-h drug exposure
and a 3-h recovery in drug-free media, a significant inhibition of
DNA, RNA and protein synthesis was observed at high concentra-
tions (50-100 JiM). At 24 h recovery in drug-free medium, the
inhibition of the synthesis of all three macromolecules was
released. A slight increase in uridine and thymidine incorporation
was apparent. Leucine uptake remained unchanged.
In order to determine whether the simultaneous inhibition ofthe
synthesis of all three macromolecules was due to an alteration of
precursor transports, the effect of PYRZ on the kinetics of label
uptake was studied. As shown in Figure 4, no significant effect
was observed on the rate ofincorporation ofthymidine at 3 h after
treatment even at 100 gM, a concentration that induced a 50%
inhibition ofmacromolecule synthesis.
Flow cytometry
The effect ofPYRZ on cell cycle was evaluatedby flow cytometry
(Figure 5). A dose-dependent increase in cell accumulation in late
S and G2+M was observed as early as 6 h after treatment. This
effect was markedly enhanced at 12 and 24 h after treatment, with
appearance at high concentrations of a sub-G, population of
cellular debris at the left portion of the histograms. Two-dimen-
sional forward light scatter DNA plots dia not show any size
reduction for these populations, thus excluding the possibility that
they might be apoptotic cells.
DNA damage
PYRZ (1 mM) was allowed to react for 2 h with the HindIIIVSphI
sequence of SV40 DNA and the damage was analysed using the
Maxam-Gilbert sequencing technique. Temozolomide induced
significant levels of guanine N-7 alkylation. In contrast, PYRZ
induced background levels ofDNA alkylation (lane A) (Figure 6).
DNA damage induced by PYRZ in OVCAR-3 cells was studied
by alkaline sucrose-density gradient as described (Zsido et al,
1991) (Figure 7). At 3 h post treatment, no DNA damage was
observed over the whole dose range (data not shown). The DNA
damage that appeared at 12 h at the high concentrations persisted
at 24 h recovery and was accompanied by significant cell death.
DISCUSSION
Ourresults clearly show that PYRZ is highly cytotoxic to OVCAR-
3 cells. Cell-killing kinetics gave sigmoidal dose-response profiles,
in contrast to those oftemozolomide which, as we recently reported
(Jean-Claude et al, 1996), showed a set of saturation curves. Thus,
although PYRZ possesses the same structural elements as temo-
zolomide (a 3-methyl-ureidotriazene portion), our data suggest that
it is not behaving as a typical ureidotriazene-containing molecule.
As shown in Figure 6, it exhibited much weaker interactions with
a 32P-labelled DNA strand in vitro than did temozolomide at a
supralethal concentration (1 mM). Surprisingly, despite inducing
background levels of DNA alkylation, PYRZ was capable of
causing significant DNAdamage inOVCAR-3 cells at 10-20 times
lower concentrations. This suggests that, in contrast to temozolo-
mide, mechanisms other than direct DNA alkylation may
contribute to the cytotoxicity ofPYRZ.
PYRZ induced an unusual pattern of dose-response profiles
for inhibition of macromolecule synthesis in OVCAR-3 cells. In
contrast to mitozolomide, temozolomide, or BCNU (Horgan et al,
1984; Jean-Claude et al, 1996), which are known to selectively
inhibit DNA synthesis, PYRZ showed a near-sigmoidal dose-
inhibition profile with a plateau at 0-75 gM, and a dose-dependent
inhibition ofthe synthesis ofall three macromolecules (DNA, RNA
and protein) at high concentrations. This inhibition is probably not
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due to precursor transport, as we found that the rate of thymidine
transport at 3 h after treatment was unaltered. At 24 h after treat-
ment, no inhibition of macromolecule synthesis was apparent even
at concentrations corresponding to 90% cell kill (50-100 gM). An
increasing trend was apparent for RNA and protein synthesis.
These effects were probably caused by the activation of several
repair mechanisms that involved macromolecule synthesis. Base
excision and long patch repairs ofDNA, induction oftranscription
and de novo protein synthesis may be the cause of the apparent
release of the inhibition of precursor incorporation. Moreover, the
inhibition of macromolecule synthesis may have little implication
in the mechanism of cell killing, as it occurred only at supratoxic
concentrations.
The persistent DNA lesions induced by PYRZ were consistent
with a progressive increase in cell cycle accumulation in late S and
G2+M in the 25-200 gM range. The block was reversed only at the
lowest concentration (12.5 gM) 24 h after treatment. Cell cycle
arrest in late S and G2+M may be related to a delay in DNA repair
processes (Hawn et al, 1995). This may cause the cells to miss
essential transcripts required to progress through to the cycle and
to die. At the concentrations that induced persistent cell cycle
arrest and DNA damage, massive cell death was observed by both
flow cytometric analysis and cell-killing kinetics.
Moreover, studies performed in our laboratory showed that
temozolomide (1) an N-7- and 06-guanine alkylator (Catapano et
al, 1987; Deans et al, 1992; Baer et al, 1993), induced delayed cell
death and cell cycle arrest in OVCAR-3 cells. Other studies by
Catapano et al (1987) showed that alkali-labile sites in L1210 cells
treated with temozolomide (1) were repaired within about 24 h.
This type of damage was therefore excluded as the lethal injury
induced by temozolomide. It should also be noted here that temo-
zolomide-treated OVCAR-3 cells arrested in late S and G2+M, but
were capable of escaping the block to later arrest in middle S, the
next round of the cycle (Jean-Claude et al, 1996; Catapano et al,
1987). Cell death induced by temozolomide may be a delayed
process highly related to point mutations induced by the 06-alkyl-
guanine adduct. In contrast, PYRZ cytotoxic activity was rapid
with maximal cell killing induced within one cell cycle time and,
more importantly, cell cycle arrest induced by PYRZ was mostly
irreversible and eventually led to cell death.
This study conclusively demonstrated that the novel heterocycle
PYRZ, despite its structural similarities to temozolomide, may
have a novel and different mechanism ofcell killing.
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